12 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of PerampanelPrimary· From first dose of study drug until perampanel was commercially available, up to approximately 1 year 5 months
Safety was assessed by monitoring adverse events (AEs), withdrawal from treatment, clinical laboratory tests (chemistry), vital signs, and weight. TEAEs were defined as AEs that emerged from the first dose of study drug to the last visit of Study 341 or on or after 30 days since the last dose of study drug in Study 341, whichever comes later, having been absent at pretreatment (Baseline of Study 332). A markedly abnormal clinical chemistry laboratory value was defined as a laboratory result that worsened in severity to meet modified National Cancer Institute (NCI) toxicity criteria of Grade 2
Non-Serious TEAEs
Group
Value
95% CI
Perampanel
6
Treatment-related TEAEs
Group
Value
95% CI
Perampanel
0
Severe TEAEs
Group
Value
95% CI
Perampanel
0
TEAEs leading to study drug dose adjustment
Group
Value
95% CI
Perampanel
0
Serious TEAE
Group
Value
95% CI
Perampanel
0
Adverse events — posted to ClinicalTrials.gov
Time frame: From first dose of study drug until perampanel was commercially available, up to approximately 1 year 5 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
To evaluate the safety and tolerability of perampanel given as an adjunctive therapy in participants with epilepsy. This study will be continued until perampanel is commercially available.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma
· EARLY_PHASE1
· recruiting
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus
· Phase 4
· terminated
NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
· Phase 2
· recruiting
NCT04309721 — Perampanel in Focal Status Epilepticus
· Phase 3
· terminated
NCT05533814 — A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizure
· Phase 4
· completed
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy
· EARLY_PHASE1
· recruiting
NCT07224191 — Hippocampal Oscillations During Exploration
· NA
· recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
· Phase 2
· recruiting
NCT07417280 — LIFUS For Neurological Disorders
· NA
· recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy
· Phase 3
· recruiting
Other Eisai Co., Ltd. trials
Trials by the same sponsor.
NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus
· Phase 2
· not yet recruiting
NCT06793709 — A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G
· recruiting
NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T
· recruiting
NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
· recruiting
NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
Last refreshed: 2 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02427607.